Biotech | 18 March 2022
Sanofi moves forward with EUROAPI listing on Euronext Paris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The investment will accelerate the overall Sarclisa development program
Machine learning approach to systems biology combined with ligand discovery platform
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Tapestri Platform powers Nature Cardiovascular Research publication that identifies two somatic mutations associated with sporadic brain blood vessel disorder
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Subscribe To Our Newsletter & Stay Updated
